First results from late-breaking Phase 3 PALOMA-3 study show

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Singapore , Canada , United States , Toronto , Ontario , Chicago , Illinois , American , Natashab Leighl , Prnewswire Johnson , Janssen Biotech Inc , None Of Janssen Research Development , American Society Of Clinical Oncology Annual Meeting , European Medicines Agency , American Lung Association , National Cancer Institute , World Health Organization , American Cancer Society , American Society Of Clinical Oncology , Johnson , Janssen Research Development , National Comprehensive Cancer Network Inc , Exchange Commission , Princess Margaret Cancer Centre , Clinical Oncology , Annual Meeting , Biologics License Application , New Drug Application , Priority Review , Practice Guidelines , Single Agent , Prescribing Information , Innovative Medicine , Janssen Research , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Advanced Non Small Cell Lung Cancer , Clinical Oncology Annual , Mutated Advanced , Metastatic Non Small Cell Lung Cancer , Accessed May , National Comprehensive Cancer Network , Participants With Advanced , Mutated Non Small Cell Lung Cancer , Amivantamab Subcutaneous , Advanced Solid Malignancies , Combination Amivantamab , Carboplatin Pemetrexed Therapy , Compared With Carboplatin Pemetrexed , Epidermal Growth Factor Receptor , Patients With Epidermal Growth Factor Receptor , Mutated Locally Advanced , Lazertinib Combination Therapy Versus Osimertinib , Locally Advanced , Human Bispecific , Met Antibody , Combination With Amivantamab , Capmatinib Combination Therapy , Combination Therapy With Amivantamab , World Health , Mutation Variants , Real World , World Conference , Lung Cancer Annual Meeting , Statistics Review , National Cancer , Year Survival , Mutant Metastatic Lung Adenocarcinoma Treated , Mol Cancer ,